Clinical trials of immunotherapy for advanced prostate cancer

Urologic Oncology

Volumn 5, Issue 6, 2000, Pages 265-273

  Kuratsukuri, Katsuyuki ^a   Nishisaka, Nobuyasu ^a   Jones, Richard F ^a   Wang, Ching Y ^a   Haas, Gabriel P ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cytokines; Gene therapy; Immunotherapy; Prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; BIOLOGICAL RESPONSE MODIFIER; CYCLOPHOSPHAMIDE; CYTOKINE; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 4; ISOTRETINOIN; LIPOSOME; ONCOVAX P; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT BETA INTERFERON; RECOMBINANT INTERLEUKIN 2; RECOMBINANT VACCINE; RETINOID; TUMOR VACCINE;

ADOPTIVE IMMUNOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DENDRITIC CELL; DRUG INDUCED DISEASE; GENE THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TREATMENT OUTCOME; TUMOR CELL; VACCINATION;

EID: 0033806176     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(00)00086-7     Document Type: Review

References (49)

1. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics. Cancer. 49:1999;8-31.
2. Crawford E.D. Challenges in the management of prostate cancer. Br J Urol. 70(suppl 1):1992;33-38.
3. Beedassy A., Cardi G. Chemotherapy in advanced prostate cancer. Semin Oncol. 26:1999;428-438.
4. Millikan R.E. Chemotherapy of advanced prostatic carcinoma. Semin Oncol. 26:1999;185-191.
5. Pienta K.J., Redman B.G., Bandekar R.et al. A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urol. 50:1997;401-406.
6. Hudes G.R., Nathan F.E., Khater C.et al. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin Oncol. 22:1995;41-45.
7. Pienta K.J., Smith D.C. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer. Semin Oncol. 24(suppl 15):1997;S15-S77.
8. Tong D., Gillick L., Hendrickson F.R. The palliation of symptomatic osseous metastases. Final results of the Study by the Radiation Therapy Oncology Group Cancer. 50:1982;893-899.
9. Zelefsky M.J., Scher H.I., Forman J.D., Linares L.A., Curley T., Fuks Z. Palliative hemiskeletal irradiation for widespread metastatic prostate cancer. A comparison of single dose and fractionated regimens Int J Radiat Oncol Biol Phys. 17:1989;1281-1285.
10. Blades R.A., Keating P.J., McWilliam L.J.et al. Loss of HLA class I expression in prostate cancer. Implications for immunotherapy Urol. 46:1995;681-686.
11. Bukowski R.M. Natural history and therapy of metastatic renal cell carcinoma. The role of interleukin-2 Cancer. 80:1997;1198-1220.
12. Nishisaka N., Jones R.F., Maini A., Morse P.D., Wang C.Y., Haas G.P. Immunotherapy and gene therapy for renal cell carcinoma. Urol Oncol. 3:1997;148-153.
13. Gutterman J., Quesada J. Clinical investigation of partially pure and recombinant DNA derived leukocyte interferon in human cancer. Tex Rep Biol Med. 41:1983;626-633.
14. Chang A.Y., Fisher H.A., Spiers A.S., Boros L. Toxicities of human recombinant interferon-α2 in patients with advanced prostate carcinoma. J Interferon Res. 6:1986;713-715.
15. van Haelst-Pisani C.M., Richardson R.L., Su J.et al. A phase II study of recombinant human alpha-interferon in advanced hormone-refractory prostate cancer. Cancer. 70:1992;2310-2312.
16. Fong C.J., Sutkowski D.M., Braun E.J.et al. Effect of retinoic acid on the proliferation and secretory activity of androgen-responsive prostatic carcinoma cells. J Urol. 149:1993;1190-1194.
17. Hwang M.S., Thomson K.L., Ahn C.H. p53-Independent induction of p21 and apoptosis by all-trans-retinoic acids and 9-cis-retinoic acid in human prostate cell lines. Proc Am Assoc Cancer Res. 36:1995;10.
18. Kelly W.K., Curley T., Liebertz C., Kim B., Scher H. Phase II trials of 13-cis-retinoic acid and interferon α2a in patients with adenocarcinoma of the prostate. Proc Am Soc Clin Oncol. 15:1996;254.
19. Higano C.S., Chielens D. α-Interferon and cis-retinoic acid in combination for treatment of hormone-refractory prostate cancer. Preliminary results of an ongoing trial Proc Am Soc Clin Oncol. 15:1996;243.
20. DiPaola R.S., Weiss R.E., Cummings K.B.et al. Effect of 13-cis-retinoic acid and alpha-interferon on transforming growth factor beta1 in patients with rising prostate-specific antigen. Clin Cancer Res. 3:1997;1999-2004.
21. Schmidt J.D., Scott W.W., Gibbons R.et al. Chemotherapy programs of the National Prostatic Cancer Project (NPCP). Cancer. 45(suppl 7):1980;1937-1946.
22. Scott W.W., Johnson D.E., Schmidt J.E.et al. Chemotherapy of advanced prostatic carcinoma with cyclophosphamide or 5-fluorouracil. Results of first national randomized study J Urol. 114:1975;909-911.
23. Daliani D.D., Eisenberg P.D., Weems J., Lord R., Fueger R., Logothetis C.J. The results of a phase II randomized trial comparing 5-fluorouracil and 5-fluorouracil plus alpha-interferon. Observations on the design of clinical trials for androgen-independent prostate cancer J Urol. 153:1995;1587-1591.
24. Bulbul M.A., Huben R.P., Murphy G.P. Interferon-β treatment of metastatic prostate cancer. J Surg Oncol. 33:1986;231-233.
25. Murphy G.P., Slack N.H. Response criteria for the prostate of the USA National Prostatic Cancer Project. Prostate. 1:1980;375-382.
26. Guinan P., Toronchi E., Shaw M., Crispin R., Sharifi R. Bacillus Calmette-Guerin (BCG) adjuvant therapy in stage D prostate cancer. Urol. 20:1982;401-403.
27. Bohle A., Gerdes J., Ulmer A.J., Hofstetter A.G., Flad H.D. Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol. 144:1990;53-58.
28. Prescott S., James K., Hargreave T.B., Chisholm G.D., Smyth J.F. Intravesical Evans strain BCG therapy. Quantitative immunohistochemical analysis of the immune response within the bladder wall J Urol. 147:1992;1636-1642.
29. Stanford J.L., Stanford C.A., Rook G.A., Grange J.M. Immunotherapy for tuberculosis - investigative and practical aspects. Clin Immunother. 1:1994;430-440.
30. Skinner M.A., Yuan S., Prestidge R., Chuk D., Watson J.D., Tan P.L. Immunization with heat-killed Mycobacterium vaccae stimulates CD8+ cytotoxic T cells specific for macrophages infected with Mycobacterium tuberculosis. Infect Immun. 65:1997;4525-4530.
31. Hrouda D., Souberbielle B.E., Kayaga J., Corbishley C.M., Kirby R.S., Dalgleish A.G. Mycobacterium vaccae (SRL172). A potential immunological adjuvant evaluated in rat prostate cancer Br J Urol. 82:1998;870-876.
32. Chikkala N.F., Lewis I., Ulcher J.et al. Interactive effects of α-interferon A/D and interleukin-2 on murine lymphokine-activated killer activity. Analysis at the effector and precursor level Cancer Res. 50:1990;1176-1182.
33. Triest J.A., Grignon D.J., Cher M.L.et al. Systemic interleukin 2 therapy for human prostate tumors in a nude mouse model. Clin Cancer Res. 4:1998;2009-2014.
34. Maffezzini M., Simonato A., Fortis C. Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL-2) and alpha-interferon (A-IFN) for stage D3 prostate carcinoma failing second-line hormonal treatment. Prostate. 28:1996;282-286.
35. Naitoh J., Tso C.L., Kaboo R., Stile A., Figlin R., Belldegrun A. Intraprostatic interleukin-2 (IL-2) gene therapy. Preliminary results of a phase I clinical trial for the treatment of locally advanced prostate cancer (CaP). J Urol. 159(suppl 5):1998;254.
36. Patel B., Naitoh J., Stiles A., Tso C.L., Figlin R., Belldegrun A. Effect of interleukin-2 (IL-2) gene therapy on prostate specific antigen in patients undergoing neoadjuvant or adjuvant gene therapy for prostate cancer. J Urol. 161(suppl 4):1999;337.
37. Vesalainen S., Lipponen P., Talja M., Syrjanen K. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer. 30A:1994;1797-1803.
38. Hrouda D., Perry M., Dalgleish A.G. Gene therapy for prostate cancer. Semin Oncol. 26:1999;455-471.
39. Simons J.W., Mikhak B. Ex-vivo gene therapy using cytokine-transduced tumor vaccines. Molecular and clinical pharmacology Semin Oncol. 25:1998;661-676.
40. Simons J.W., Mikhak B., Chang J.F.et al. Clinical activity and broken immunologic tolerance from ex vivo GM-CSF gene transduced prostate cancer vaccines. J Urol. 161(suppl 4):1999;51.
41. Tjoa B.A., Simmons S.J., Bowes V.A.et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate. 36:1998;39-44.
42. Salgaller M.L., Lodge P.A., McLean J.G.et al. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate. 35:1998;144-151.
43. Tjoa B.A., Erickson S.J., Bowes V.A.et al. Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate. 32:1997;272-278.
44. Harris D.T., Matyas G.R., Gomella L.G.et al. Immunologic approaches to the treatment of prostate cancer. Semin Oncol. 26:1999;439-447.
45. Zhang S., Zhang H.S., Reuter V.E., Slovin S.F., Scher H.I., Livingston P.O. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res. 4:1998;295-302.
46. Slovin S.F., Ragupathi G., Adluri S.et al. Carbohydrate vaccines in cancer. Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man Proc Natl Acad Sci USA. 96:1999;5710-5715.
47. Paoletti E., Tartaglia J., Cox W.I. Immunotherapeutic strategies for cancer using poxvirus vectors. Ann NY Acad Sci. 690:1993;292-300.
48. Hodge J.W., Schlom J., Donohue S.J.et al. A recombinant vaccinia virus expressing human prostate-specific antigen (PSA). Safety and immunogenicity in a non-human primate Int J Cancer. 63:1995;231-237.
49. Sanda M.G., Smith D.C., Charles L.G.et al. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urol. 53:1999;260-266.